Literature DB >> 29892936

Treatment selection for esophageal cancer: evaluation from a nationwide database.

Yasuo Hamamoto1,2, Naoki Sakakibara3, Fumio Nagashima4, Yuko Kitagawa5, Takahiro Higashi3.   

Abstract

BACKGROUND: Most elderly patients poorly tolerate the standard treatment for esophageal cancer; however, little information is available regarding the appropriateness of non-standard esophageal cancer treatments for those patients. This study aims to analyze the treatment costs and completion rates of patients undergoing a real-world treatment for esophageal cancer to elucidate the treatment selection and its quality.
MATERIALS AND METHODS: We analyzed treatment costs and completion rates for patients with esophageal cancer and analyzed these data relative to patient age and center volumes. Patients with esophageal cancer [UICC, TMN, Clinical stage II/III (excluding T4)] who were diagnosed in 2013 were analyzed. Patients were classified into five groups defined as follows: surgical therapy, chemotherapy, concurrent chemoradiotherapy (CCRT), modified concurrent chemoradiotherapy (mCRT), and radiotherapy (RT).
RESULTS: Mean and median age of patients who received surgery and CCRT were comparable; however, patients who underwent mCRT and RT tended to be older. Medical costs associated with surgery were higher than costs associated with other non-surgical treatments. Cost and completion rate of chemoradiotherapy did not differ between CCRT and mCRT; however, both had higher completion rates compared to that of RT. Surgical expenses tended to be the highest in low-volume centers and the lowest in high-volume centers.
CONCLUSION: Treatment of esophageal cancer at high-volume centers seems well balanced compared with medium- to low-volume centers. mCRT was widely performed and comparable in medical cost to CCRT, although additional clinical impacts were unclear.

Entities:  

Keywords:  Chemoradiotherapy; Costs of care; Elderly; Esophageal cancer; Hospital-based cancer registries

Mesh:

Substances:

Year:  2018        PMID: 29892936     DOI: 10.1007/s10388-018-0605-0

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


  23 in total

1.  Trends in hospital volume and operative mortality for high-risk surgery.

Authors:  Jonathan F Finks; Nicholas H Osborne; John D Birkmeyer
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

2.  Inter-institutional survival heterogeneity in chemoradiation therapy for esophageal cancer: exploratory analysis of the JCOG0303 study.

Authors:  Yasuo Hamamoto; Junki Mizusawa; Hiroshi Katayama; Kenichi Nakamura; Ken Kato; Yasuhiro Tsubosa; Satoshi Ishikura; Hiroyasu Igaki; Masayuki Shinoda; Haruhiko Fukuda; Yuko Kitagawa; Nobutoshi Ando
Journal:  Jpn J Clin Oncol       Date:  2016-01-31       Impact factor: 3.019

3.  Impact of center size and experience on outcomes in head and neck cancer.

Authors:  June Corry; Lester J Peters; Danny Rischin
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

4.  Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus.

Authors:  Mohan Suntharalingam; Jennifer Moughan; Lawrence R Coia; Mark J Krasna; Lisa Kachnic; Daniel G Haller; Christopher G Willet; Madhu J John; Bruce D Minsky; Jean B Owen
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort.

Authors:  Grace L Smith; Benjamin D Smith; Thomas A Buchholz; Zhongxing Liao; Melenda Jeter; Stephen G Swisher; Wayne L Hofstetter; Jaffer A Ajani; Mary F McAleer; Ritsuko Komaki; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

6.  A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.

Authors:  Satoshi Takeuchi; Atsushi Ohtsu; Toshihiko Doi; Takashi Kojima; Keiko Minashi; Kiyomi Mera; Tomonori Yano; Makoto Tahara; Manabu Muto; Keiji Nihei
Journal:  Am J Clin Oncol       Date:  2007-12       Impact factor: 2.339

7.  Esophagectomy in patients 80 years of age and older with carcinoma of the thoracic esophagus.

Authors:  Masaru Morita; Akinori Egashira; Rintaro Yoshida; Keisuke Ikeda; Kippei Ohgaki; Kotaro Shibahara; Eiji Oki; Noriaki Sadanaga; Yoshihiro Kakeji; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

8.  Physiology, not chronology, dictates outcomes after esophagectomy for esophageal cancer: outcomes in patients 80 years and older.

Authors:  Sheraz R Markar; Donald E Low
Journal:  Ann Surg Oncol       Date:  2012-11-02       Impact factor: 5.344

9.  Monitoring and evaluating the quality of cancer care in Japan using administrative claims data.

Authors:  Momoko Iwamoto; Fumiaki Nakamura; Takahiro Higashi
Journal:  Cancer Sci       Date:  2015-11-30       Impact factor: 6.716

10.  Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma.

Authors:  Yasuo Hamamoto; Masanori Nojima; Yu Aoki; Takeshi Suzuki; Kenta Kawasaki; Kenro Hirata; Yasutaka Sukawa; Akira Kasuga; Hirofumi Kawakubo; Hiroya Takeuchi; Koji Murakami; Hiromasa Takaishi; Takanori Kanai; Yuko Kitagawa
Journal:  Esophagus       Date:  2017-05-23       Impact factor: 4.230

View more
  3 in total

1.  LncRNA MAGI2-AS3 Overexpression Sensitizes Esophageal Cancer Cells to Irradiation Through Down-Regulation of HOXB7 via EZH2.

Authors:  Wenfang Cheng; Xiuling Shi; Mingqiang Lin; Qiwei Yao; Jiayu Ma; Jiancheng Li
Journal:  Front Cell Dev Biol       Date:  2020-11-24

Review 2.  Management of elderly patients with esophageal squamous cell cancer.

Authors:  Yasuo Hamamoto; Kentaro Murakami; Ken Kato; Yuko Kitagawa
Journal:  Jpn J Clin Oncol       Date:  2022-08-05       Impact factor: 2.925

Review 3.  p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinoma.

Authors:  Hideaki Shimada
Journal:  Ann Gastroenterol Surg       Date:  2018-06-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.